2-amino-2-(2-(4-(1-oxo-5-phenylpentyl)phenyl)ethyl)propane-1,3-diol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-amino-2-(2-(4-(1-oxo-5-phenylpentyl)phenyl)ethyl)propane-1,3-diol
• 英文别名: 2-amino-2-(2-(4-(5-phenylpentanoyl)phenyl)ethyl)propan-1,3-diol；1-[4-[3-Amino-4-hydroxy-3-(hydroxymethyl)butyl]phenyl]-5-phenylpentan-1-one
• 化学式: C₂₂H₂₉NO₃
• 分子量: 355.477
• InChiKey: FLBPTSOAFRMSPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  26
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-acetamido-2-{2-[4-(1,1-ethylenedioxy-5-phenylpentyl)phenyl]ethyl}propane-1,3-diol 在 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 2-amino-2-(2-(4-(1-oxo-5-phenylpentyl)phenyl)ethyl)propane-1,3-diol
  参考文献：
  名称：

  2-AMINOPROPANE-1,3-DIOL COMPOUNDS, MEDICINAL USE THEREOF, AND INTERMEDIATES IN SYNTHESIZING THE SAME

  摘要：

  公开号：

  EP1002792B1

文献信息

• [EN] PHOSPHINANE COMPOUNDS WITH IMMUNOMODULATING ACTIVITY<br/>[FR] COMPOSES DE PHOSPHINANE A EFFET IMMUNOMODULATEUR
  申请人：MITSUBISHI PHARMA CORP

  公开号：WO2005014603A1

  公开（公告）日：2005-02-17

  The invention is directed to a phosphinane compound having a unique immunomodulating activity, a process for a preparation thereof, a pharmaceutical composition containing the same, and a method of preventing or treating disorders or diseases mediated by T lymphocytes by administering the compound to a subject in need of treatment.

  这项发明涉及一种具有独特免疫调节活性的膦环化合物，其制备方法，含有该化合物的药物组合物，以及通过向需要治疗的受试者施用该化合物来预防或治疗由T淋巴细胞介导的疾病或疾病的方法。
• 2-Amino-propanol derivatives
  申请人：——

  公开号：US20040147490A1

  公开（公告）日：2004-07-29

  Compounds of formula (i), wherein m, R, R 1 , and R 3 to R 6 are as defined in the specification, m, is 1, 2 or 3 and X is O or a direct bond, and the corresponding unphosporylated compounds have interesting properties, e.g. immunosuppressive properties. 1

  式子为(i)的化合物，其中m，R，R1和R3到R6如规范所定义，m为1，2或3，X为O或直接键，并且相应的未磷酸化化合物具有有趣的性质，例如免疫抑制性质。
• 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1319651A2

  公开（公告）日：2003-06-18

  The present invention relates to a compound of the general formula wherein m is 0 to 9, and R1a, R2a, R3a and R4a are the same or different and each is a hydrogen or an acyl, with the proviso that m is not 4; a pharmaceutically acceptable acid addition salt thereof or a hydrate thereof; a pharmaceutical comprising this compound; and a pharmaceutical composition comprising this compound and a pharmaceutically acceptable carrier. The compound of the present invention shows superior immunosuppressive action with less toxicity and higher safety, and is useful as a drug for preventing or suppression of rejection of organs or bone marrow transplantation, or as a drug for prevention or treatment of various autoimmune diseases or allergic diseases.

  本发明涉及通式如下的化合物 其中m为0至9，R1a、R2a、R3a和R4a相同或不同，且各自为氢或酰基，但m不为4；其药学上可接受的酸加成盐或其水合物；包含该化合物的药物；以及包含该化合物和药学上可接受的载体的药物组合物。本发明的化合物显示出优越的免疫抑制作用，毒性小，安全性高，可作为预防或抑制器官或骨髓移植排斥反应的药物，或作为预防或治疗各种自身免疫性疾病或过敏性疾病的药物。
• MEDICINAL COMPOSITION AS IMMUNOSUPPRESSANT
  申请人：Sankyo Company, Limited

  公开号：EP1782804A1

  公开（公告）日：2007-05-09

  A medicinal composition useful as an excellent preventive or therapeutic agent for diseases relating to immunization. The medicinal composition comprises at least one member selected from the group consisting of HMG-CoA reductase inhibitors and at least one member selected from the group consisting of an amino alcohol derivative represented by the following general formula (I), a pharmacologically acceptable salt of the derivative, and a pharmacologically acceptable ester of the derivative. [In the formula, R1 and R2 are the same or different and each represents a hydrogen, etc.; R3 represents lower alkyl, etc.; R4 represents hydrogen, etc.; R5 represents hydrogen, halogeno, phenyl, etc.; X represents vinylene (CH=CH), methylated nitrogen, etc.; Y represents a single bond, oxygen, sulfur, or carbonyl; Z represents C1-C8 alkylene, etc. ; n is 2 or 3; and the substituents a represent lower alkyl, lower alkoxy, phenyl, etc.]

  一种药物组合物，可作为与免疫有关的疾病的优良预防或治疗剂。该药物组合物包括至少一种选自 HMG-CoA 还原酶抑制剂和至少一种选自以下通式（I）所代表的氨基醇衍生物、该衍生物的药理学上可接受的盐和该衍生物的药理学上可接受的酯组成的组。 [式中，R1 和 R2 相同或不同，各自代表氢等；R3 代表低级烷基等；R4 代表氢等；R5 代表氢、卤素、苯基等；X 代表乙烯基（CH=CH）、甲基化氮等；Y 代表单键、氧、硫或羰基；Z 代表 C1-C8 亚烷基等；n 为 2 或 3；取代基 a 代表低级烷基、低级烷氧基、苯基等。］
• Organic compounds comprising an S1P receptor agonist and their therapeutic use
  申请人：Novartis AG

  公开号：EP1905434A1

  公开（公告）日：2008-04-02

  The present invention provides a solid pharmaceutical composition suitable for oral administration, comprising an S1P receptor agonist in the absence of a sugar alcohol.

  本发明提供了一种适合口服的固体药物组合物，其中包含一种不含糖醇的 S1P 受体激动剂。